Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates Zura Bio (Nasdaq: ZURA) reported full year 2025 results and corporate updates on March 19, 2026. Key points: $109.4M cash as of December 31, 2025; completed a February 2026 public offering for ~$144M gross proceeds; pro‑forma cash expected to fund operations through at least end of 2028.Clinical progress includes two ongoing Phase 2 tibulizumab studies: TibuSHIELD (HS) expanded to 225 participants with topline data expected Q4 2026, and TibuSURE (SSc) topline data expected H1 2027.

#ZURA Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/ZURA/zura-bio-repor...

Zura Bio Reports Business Updates and Outlook for 2026 Zura Bio (Nasdaq: ZURA) provided 2026 business updates and an outlook focused on tibulizumab, a bispecific antibody targeting IL-17 and BAFF for hidradenitis suppurativa (HS) and systemic sclerosis (SSc).Key developments: the Phase 2 TibuSHIELD HS trial is expanding enrollment to 225 participants Q4 2026. The Phase 2 TibuSURE SSc study is enrolling with topline data expected in H1 2027. The company says cash and cash equivalents are expected to fund planned operations through 2027, covering the anticipated readouts.

#ZURA Zura Bio Reports Business Updates and Outlook for 2026

www.stocktitan.net/news/ZURA/zura-bio-repor...

Anyways, join Joui now and get a free fancy card 👍 #gntm #gintama #gintamafanart #art #zura

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#U, #ZURA, #GSK, #VRT, #WDC

#OptionFlow #OptionsTrading #Trading

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates Zura Bio Limited, a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates. “Both tibulizumab studies advanced during the quarter,” said Kiran...

#ZURA Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/ZURA/zura-bio-repor...

🚀 Exciting times for #ZURA! Trading at $3.925 with bullish momentum, supported by an 8-day EMA of $3.44 and a high RSI of 74. 📈 Positive MACD hints at more gains, but watch for short-term pullbacks. Consider going LONG with targets at $4.10 & $4.25. Stay sharp! 💡 #Stocks #FeetrAI

Most Searched, Tuesday September 30, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Sept 30th - #ONDS #NUAI #NVTS #DPRO #IBG #ZURA #PLUG #RZLB #WRD #TLRY #SRPT #SBET #RR #ORIC #NNE #LUNR #LAC #IDR #CERS #BETR - More: crystalequityresearch.com/most-searche... - #smallcap

🚀 Exciting times for #ZURA! With strong bullish momentum and trading volume soaring, this biotech stock is on the move. Consider a long position at $4.30, targeting $4.50 & $4.70. But stay sharp—market volatility and sector news could shake things up! 📈 #Biotech #Stocks

🚀 Exciting times for #ZURA! With a price of $3.93 and trading volume soaring, this biotech stock is on the move! 📈 RSI indicates it's overbought, but MACD shows bullish vibes. Consider a short-term long at $3.90 with targets at $4.20 & $4.50. Stay sharp! #Biotech #Stocks

Trade Alerts, Monday September 29, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading Mon Sept 29th - #YCBD #ZURA #VALN #TLRY #SCOR #RDHL #NTWK #INVZ #GRWG #CRON #ACB #WOLF #CGC - More: crystalequityresearch.com/trade-alerts... - #smallcap

🚀 Exciting times for #ZURA! Trading volume is soaring thanks to promising cancer treatment results. With bullish technicals and strong buying momentum, consider a LONG position at $3.35. Target: $3.70 & $4.00. Stop loss: $3.10. High confidence in hitting the first target! 📈 #FeetrAI

Officially endorsed "heroines" in the new "Pray" PV for Gintama !!! ¿? #gintama #zura #katsurakotarou

Zura Bio's $154.5M Cash Runway Extends to 2027 as Key Clinical Trials Progress Clinical-stage biotech reports strong Q2 financials with $154.5M cash position and milestone progress in HS and systemic sclerosis trials. Extended runway through 2027. Get details.

#ZURA Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/ZURA/zura-bio-repor...

Zura Bio Announces Chief Financial Officer Transition Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren will succeed Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition.Hyllengren brings over 20 years of financial leadership experience in life sciences and biotechnology. He previously served as COO and CFO at Atara Biotherapeutics, where he managed strategic finance, capital markets, operational planning, and other key functions. Before that, he spent 15 years at Amgen in various roles including corporate finance, investor relations, and business development.Badial, who joined Zura Bio in March 2023 during its business combination with JATT Acquisition Corporation, helped develop the company's financial systems and participated in capital-raising initiatives during his tenure.

#ZURA Zura Bio Announces Chief Financial Officer Transition

www.stocktitan.net/news/ZURA/zura-bio-annou...

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa Zura Bio (NASDAQ: ZURA) has launched TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS). The study will be the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in HS patients. The trial will enroll approximately 180 adults across the United States, Canada, and Europe, spanning 28 weeks with a 16-week primary efficacy assessment and 12-week safety follow-up, plus an optional open-label extension. Topline results for the primary efficacy endpoint are expected in Q3 2026. This launch follows the December 2024 initiation of TibuSURE, another Phase 2 study evaluating tibulizumab in systemic sclerosis patients.

#ZURA Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

www.stocktitan.net/news/ZURA/zura-bio-launc...

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates Zura Bio (NASDAQ: ZURA) reported its Q1 2025 financial results and corporate updates. The company ended Q1 with $170.6 million in cash, expected to fund operations through 2027. Key developments include advancing the Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis and preparing for a Phase 2 trial in hidradenitis suppurativa, set to begin in Q2 2025. The company reported a net loss of $17.4 million ($0.19 per share) compared to $7.7 million ($0.02 per share) in Q1 2024. R&D expenses increased to $10.5 million from $3.6 million year-over-year, while G&A expenses rose to $8.8 million from $4.8 million. The company also strengthened its team by appointing Kate Dingwall as SVP of Development Operations.

#ZURA Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/ZURA/zura-bio-repor...

Charts of the Day - small-cap stocks forming bullish rising three methods candlestick signal, Tue Mar 25th - #YEXT #ZURA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Zura Bio Secures $176.5M War Chest, Advances Clinical Pipeline with Reduced Losses Latest financial results reveal $176.5M cash position and 34% reduced losses. Phase 2 trials advance in systemic sclerosis and hidradenitis suppurativa. Full analysis inside.

#ZURA Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/ZURA/zura-bio-repor...

I'll be actively developing my bluesky account from now on!
💗💗💗

#leagueoflegends #artoflegends #zura

He is going to be the ikemen sitting near the window, with the sunlight falling on him ;_; #KatsuraKotaro #gintama #zura

News; ( NASDAQ: #ZURA ) Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

#StockMarket #News

digital drawing of Zura sitting very serious on a plane wing. his hair is blowing in the wind. the background is a photo of the clouds from inside a plane.

A gremlin on the wing. #gintama #zura

#ZURA Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/ZURA/zura-bio-to-pr...

#ZURA Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

www.stocktitan.net/news/ZURA/zura-bio-annou...

😫ひぁ〜ッス疲れたし腹ペコだし😮‍💨　？　なんズラ？コレなんズラ⁉️ 特大鶏そぼろ入り厚焼き卵だってぇ〜腹減りすぎたから助かるZE🙌
🥢いただきズラ🙏

#晩メシ #残業 #残業帰り #厚焼き卵 #腹ペコ #ZURA #甲州弁

chibis

#joui4 #銀魂 #gintama #gintoki #sakamoto #zura #katsura #takasugi

O sea, que la duración máxima de los vídeos que se pueden subir es de 1 minuto... Sorry not sorry :) #gintama #zura #katsura